Marketbeat.com reported that Gilead Sciences, the American biotechnology company, recently suffered a large drop in short interest during July. Based on an average daily volume of 10,218,237 shares, the short-interest ratio is currently 2.0 days.

When seeing the average daily volume of 10,218,237 shares, the short-interest ratio is currently 2.0 days. It has been found that presently near about 1.4% of the company's shares are short sold.

It has been said that COO John F. Milligan sold 100,000 shares of the business's stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $114.44, for a total transaction of $11,444,000.00. This sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

In addition, Director John Francis Cogan sold 27,000 shares of the business's stock in a transaction dated Friday, June 26th. It was found that the stock was sold at an average price of $120.13, for a total transaction of $3,243,510.00.

Gilead Sciences has also been a major part of discussion among analyst reports. Vetr downgraded shares of Gilead Sciences from a 'strong-buy' rating to a 'buy' rating.

Bank of America in a research note on Wednesday reissued an "underperform" rating and set a $107.00 price objective on shares of Gilead Sciences.

JPMorgan Chase & Co. reaffirmed an 'overweight' rating on shares of Gilead Sciences in a report on Wednesday. On the other hand, Morgan Stanley reaffirmed an 'overweight' rating and set a $125.00 price target on shares of Gilead Sciences in a research report on Wednesday.